Publicacions en col·laboració amb investigadors/es de Thomas Jefferson University (5)

2021

  1. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma

    Cancer Medicine, Vol. 6, Núm. 1, pp. 36-44

2015

  1. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

    Annals of Oncology, Vol. 26, Núm. 4, pp. 774-779

2014

  1. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

    Biomarker Research, Vol. 2, Núm. 1